Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (1-10 of 315) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Cell cycle-associated kinases as targets for therapy in lung cancerD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Taking aim at ALK across the blood-brain barrierD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
The Magic of ADAURA?D Ross Camidge
Expert Opinion on Biological Therapy|July 11, 2008
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumorsD Ross Camidge
The Lancet. Respiratory Medicine|October 20, 2019
Next-generation ALK inhibitors: is the median the message?D Ross Camidge
The Lancet. Oncology|August 17, 2013
Icotinib: kick-starting the Chinese anticancer drug industryD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Mitotic inhibitorsD Ross Camidge
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignoreD Ross Camidge
Journal of Oncology Practice|April 12, 2017
Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung CancerD Ross Camidge
Clinical Lung Cancer|August 8, 2007
The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancerD Ross Camidge
Pageof 32

Showing results (1-10 of 315) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Cell cycle-associated kinases as targets for therapy in lung cancerD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Taking aim at ALK across the blood-brain barrierD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
The Magic of ADAURA?D Ross Camidge
Expert Opinion on Biological Therapy|July 11, 2008
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumorsD Ross Camidge
The Lancet. Respiratory Medicine|October 20, 2019
Next-generation ALK inhibitors: is the median the message?D Ross Camidge
The Lancet. Oncology|August 17, 2013
Icotinib: kick-starting the Chinese anticancer drug industryD Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Mitotic inhibitorsD Ross Camidge
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignoreD Ross Camidge
Journal of Oncology Practice|April 12, 2017
Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung CancerD Ross Camidge
Clinical Lung Cancer|August 8, 2007
The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancerD Ross Camidge
Pageof 32